News & Events
Disc Medicine Reports Second Quarter 2023 Financial Results and Provides Business Update
Presented positive initial safety and efficacy data from the BEACON trial at the European Hematology Association (EHA) Congress in June 2023; data from all patients in BEACON to be presented year-end 2023 Initiated a phase 1/2 study of bitopertin in patients with Diamond-Blackfan Anemia who have
More News
Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
Positive updates across all programs, including updates from ongoing clinical studies and new translational data in preclinical models supporting use in...
read more
Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting
Demonstrated durable hematologic response across all patient subgroups, regardless of baseline transfusion status and concomitant JAK inhibitor therapy Phase 2 study in...
read more
Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update
Completed a successful end of Phase 2 meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP), reaching alignment on all proposed...
read more